At a glance
ClinicalIndex Comparison Record- ✓Age >18 years old
- ✓Persistent erythema associated with rosacea
- ✓Investigator Global Assessment score 2–5 (mild to moderate rosacea)
- ✓Access to computer and internet
- ✕Initiation or change in dose of systemic anti-inflammatory medication within 4 weeks of baseline
- ✕Topical rosacea therapy within 2 weeks of baseline
- ✕Systemic corticosteroids within 4 weeks of baseline
- ✕Known allergy or sensitivity to brimonidine topical gel 0.33% or components
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Internet Surveys and Their Impact on Adherence and Quality of Life to Mirvaso for Rosacea
In Brief
A Phase 4 clinical trial evaluating brimonidine topical gel 0.33% & survey and brimonidine topical gel 0.33% & SOC for Rosacea. Completed, enrolled 20 participants across 1 site.
Detailed Summary
An investigator-blinded, prospective, 6 month study of subjects with persistent erythema associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All subjects will receive standard-of-care brimonidine topical gel, 0.33% with instructions to apply it once daily per package insert. Adherence will be assessed using weekly internet surveys to document how often the medication is being used, as well as reminders about rosacea triggers and general use of brimonidine.
Study Details
Timeline
Interventions
The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
All subjects will receive standard-of-care brimonidine topical gel 0.33%